133 related articles for article (PubMed ID: 2730091)
21. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
[TBL] [Abstract][Full Text] [Related]
22. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
23. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
26. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
27. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
28. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
29. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
Gerrard G; Payne E; Baker RJ; Jones DT; Potter M; Prentice HG; Ethell M; McCullough H; Burgess M; Mehta AB; Ganeshaguru K
Haematologica; 2004 Jul; 89(7):782-90. PubMed ID: 15257929
[TBL] [Abstract][Full Text] [Related]
30. Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Jehn U; Heinemann V
Anticancer Res; 1993; 13(2):379-81. PubMed ID: 8517650
[TBL] [Abstract][Full Text] [Related]
31. [Late results of the treatment of acute granulocytic leukemia in adults].
Perilov AA; Volkova MA; Frenkel' MA
Ter Arkh; 1989; 61(7):8-11. PubMed ID: 2588148
[TBL] [Abstract][Full Text] [Related]
32. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
33. AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
Maschmeyer G; Willborn K; Heit W
Leuk Lymphoma; 1992 Nov; 8(4-5):365-9. PubMed ID: 1290961
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
[TBL] [Abstract][Full Text] [Related]
36. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
[TBL] [Abstract][Full Text] [Related]
37. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
38. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
[TBL] [Abstract][Full Text] [Related]
39. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
[TBL] [Abstract][Full Text] [Related]
40. Unfavourable outcome of a patient with M2 acute non lymphocytic leukemia and a 47,XY,t(5;7)(q34;q21), +8 karyotype.
Testoni N; Zaccaria A; Celso B; Tura S
Haematologica; 1991; 76(1):65-8. PubMed ID: 2055562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
